The Impact of COVID-19 Comorbidities on Return to Work
White Paper Summary
In 2020, the coronavirus disease 2019 (COVID-19) pandemic had a widespread impact and presented unprecedented challenges to many sectors of business, including the healthcare system. One facet of the pandemic where evidence is still being developed and analyzed is the impact of comorbidities on the disease course and potential return to work (RTW) considerations. Inadequate comorbidity management can lead to longer duration of acute illness, higher total healthcare costs, more temporary disability days, and higher litigation rates.
To learn more about ODG by MCG, please visit their website.